This study is being done to evaluate the antihypertensive efficacy and tolerability of
MK-7145 in participants with mild-to-moderate hypertension.
Inclusion criteria:
- Diagnosis of essential hypertension
- Body mass index (BMI) ≤35 kg/m^2
- Participant in general good health
- No history of clinically significant arrhythmias or clinically significant
abnormality on electrocardiogram (ECG)
- No history of clinically significant cardiac disease
- Treatment-naïve or taking up to 2 antihypertensive therapeutic agents
- Non-smoker and/or has not used nicotine or nicotine-containing products for at least
6 months
Exclusion criteria:
- Participant has low plasma potassium
- History of stroke, chronic seizures, or major neurological disorder
- History of clinically significant endocrine, gastrointestinal, cardiovascular,
hematological, hepatic, immunological, renal, respiratory, or genitourinary
abnormalities or diseases
- History of osteoporosis
- Active or history of nephrocalcinosis, nephrolithiasis or hypercalciuria
- Orthostatic change in vital sign measurements while going from a semi-recumbent to
standing position accompanied by symptoms
- Functional disability that can interfere with rising from a semi-recumbent position
to the standing position
- History of malignant neoplastic disease. Exceptions: (1) adequately treated
non-melanomatous skin carcinoma; (2) other malignancies which have been successfully
treated >10 years prior to the prestudy (screening) visit, (3) unlikely to sustain a
recurrence
- Participant is unable to refrain from the use of prescription and non-prescription
drugs such as high-dose aspirin (≥325 mg/day), strong/moderate Cytochrome P450 3A4
(CYP3A4) inhibitors (such as ritonavir, indinavir, nelfinavir, erythromycin,
telithromycin, clarithromycin, chloramphenicol, fluconazole, ketoconazole,
itraconazole, nefazodone, aprepitant, verapamil, or diltiazem) as well as
strong/moderate CYP3A4 inducers (such as phenytoin, carbamazepine, oxcarbazepine,
phenobarbital, efavirenz, nevirapine, etravirine, rifampicin, modafinil, St Johns
Wort, cyproterone, or progestin) beginning approximately 2 weeks (or 5 half-lives),
prior to administration of the initial dose of study drug until the post study visit
- Current use of non-steroidal anti-inflammatory drugs (NSAIDs) other than low dose
aspirin, aluminum- or magnesium-containing antacids, sucralfate, metal cations such
as iron, multivitamins containing iron or zinc that cannot be discontinued at least 2
weeks (or 5 half-lives) prior to administration of the initial dose of study drug
until the post study visit
- Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of
alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces],
wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day
- Participant consumes excessive amounts, defined as greater than 6 servings (1 serving
is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other
caffeinated beverages per day
- Major surgery, donation or lost 1 unit of blood (approximately 500 mL), or
participation in another investigational study within 4 weeks prior to the prestudy
(screening)
- History of significant multiple and/or severe allergies (including latex allergy), or
has had an anaphylactic reaction or significant intolerability to prescription or
non-prescription drugs or food
- Regular use of any illicit drugs or history of drug abuse within approximately 6
months
- Dehydration or volume-depletion
